<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00260728</url>
  </required_header>
  <id_info>
    <org_study_id>S2100</org_study_id>
    <secondary_id>G050151</secondary_id>
    <nct_id>NCT00260728</nct_id>
  </id_info>
  <brief_title>The Boston Scientific ACCESS Trial</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>ACCESS: Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maquet Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maquet Cardiovascular</source>
  <brief_summary>
    <textblock>
      The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of&#xD;
      the Fusion™ Vascular Access Graft for patients in need of early vascular access for&#xD;
      hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of&#xD;
      the Fusion™ Vascular Access Graft for patients in need of early vascular access for&#xD;
      hemodialysis. The primary objective is to demonstrate that secondary patency at 6 months for&#xD;
      the Fusion™ Vascular Access Graft is not less than an objective performance criterion (OPC)&#xD;
      minus a clinically relevant margin (δ). The OPC represents secondary patency at 6 months for&#xD;
      the standard of care access grafts.&#xD;
&#xD;
      The secondary safety endpoint is the occurrence of CEC-adjudicated device or procedure&#xD;
      related adverse events through 24 months post implant procedure, or through discharge for&#xD;
      patients with unsuccessful device implantation. Secondary efficacy endpoints include:primary&#xD;
      patency; primary assisted patency; ability to revise a failed graft; early access capability;&#xD;
      time to hemostasis.&#xD;
&#xD;
      Subjects will undergo a thorough medical assessment and physical examination pre-procedure&#xD;
      and will be assessed peri-procedure. Enrolled subjects with a device implanted will be&#xD;
      evaluated at 1, 6, 12, 18 and 24 months post implant procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Secondary patency at 6 months as determined by ability of the graft to be used for vascular access for hemodialysis</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Renal Disease</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vascular access graft implantation</intervention_name>
    <description>vascular access graft implantation</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Need for early dialysis access (≤72 hours after implantation):&#xD;
&#xD;
               -  Initiation of maintenance dialysis is recommended per K/DOQI or institutional&#xD;
                  guidelines; or&#xD;
&#xD;
               -  Patient is currently receiving dialysis via catheter&#xD;
&#xD;
          2. No prior implantation of synthetic graft in the arm to be treated&#xD;
&#xD;
          3. Life expectancy of at least 2 years, based on physician's assessment of medical&#xD;
             condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient younger than 18 years of age&#xD;
&#xD;
          2. Any stenosis in the veins proximal to (downstream of) implant site, as determined&#xD;
             previously or by current ultrasound&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Bleeding disorder, e.g., low platelet count (&lt;50,000), hypercoagulable state, e.g.,&#xD;
             antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V&#xD;
             Leiden; circulating Lupus anticoagulant; current, active heparin-induced&#xD;
             thrombocytopenia; Protein C or S deficiency; or history of recurrent deep vein&#xD;
             thrombosis not related to AV access.&#xD;
&#xD;
          5. Active malignancy, e.g., condition either being treated or considered untreatable&#xD;
&#xD;
          6. Active systemic infection, e.g., condition either being treated or considered&#xD;
             untreatable&#xD;
&#xD;
          7. Uncontrolled major symptomatic medical problem, e.g., undiagnosed severe pain,&#xD;
             metabolic disturbance, fever, etc.&#xD;
&#xD;
          8. Likelihood of poor compliance to required dialysis protocol, e.g., history of poor&#xD;
             attendance to required clinic sessions or non-compliance to medication&#xD;
&#xD;
          9. Mental incapacity; inability to understand treatment instructions&#xD;
&#xD;
         10. Currently participating in another investigational drug or device study that&#xD;
             clinically interferes with the endpoints of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine, Barnes Jewish Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach VA Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Healthcare System</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York - Presbyterian, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern / VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 30, 2005</study_first_submitted>
  <study_first_submitted_qc>November 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular access</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

